Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ValbiotisXPAR:ALVAL -1.30%48 Debt-to-Equity is 0.73 as of Dec. 2025, which is 35% above its 10-year median of 0.54. GuruFocus rates XPAR:ALVAL with a GF Score™ of 48/100 and a GF Value™ of €1.46 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 1,743 Consumer Packaged Goods companies, Valbiotis ranks worse than 68.16% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Valbiotis's Debt-to-Equity or its related term are showing as below:
XPAR:ALVAL'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.17 Med: 0.54 Max: 2.19
Current: 0.73
During the past 11 years, the highest Debt-to-Equity Ratio of Valbiotis was 2.19. The lowest was 0.17. And the median was 0.54.
XPAR:ALVAL's Debt-to-Equity is ranked worse than 68.16% of 1743
companies
in the Consumer Packaged Goods industry
Industry Median: 0.41
vs XPAR:ALVAL: 0.73
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Valbiotis Debt-to-Equity Related Terms
Valbiotis Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Valbiotis's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Packaged Foods subindustry, Valbiotis's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Valbiotis Debt-to-Equity vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Valbiotis's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Valbiotis's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Valbiotis (XPAR:ALVAL) has a Debt-to-Equity of 0.73 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Valbiotis and its competitors. This is 35% above median its historical median of 0.54. Over the past decade, Valbiotis' Debt-to-Equity has ranged from 0.17 to 2.19. According to the industry distribution chart, Valbiotis ranks #1188 out of 1743 companies in the Consumer Packaged Goods industry, placing it in the top 68.2%.
Is Valbiotis' Debt-to-Equity too high?
Valbiotis' current Debt-to-Equity of 0.73 is 35% above median its 10-year median of 0.54. Over the past 10 years, this metric has ranged from a low of 0.17 to a high of 2.19. The Consumer Packaged Goods industry median Debt-to-Equity is 0.41. Valbiotis' value of 0.73 is 78% above this industry median. Based on the distribution chart, Valbiotis ranks #1188 out of 1743 companies in the Consumer Packaged Goods industry, which is below the industry midpoint. Overall, Valbiotis has a GF Score™ of 48/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Valbiotis' Debt-to-Equity compare to KHC and GIS?
According to the Consumer Packaged Goods industry distribution chart, Valbiotis ranks #1188 out of 1743 companies for Debt-to-Equity. This places Valbiotis in the lower half of its industry. The industry median Debt-to-Equity is 0.41. Valbiotis' value of 0.73 is 78% above this benchmark. Historically, Valbiotis' own Debt-to-Equity has ranged from 0.17 to 2.19 over the past decade. While the company's 10-year median is 0.54 vs. the industry median of 0.41, Valbiotis has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Consumer Packaged Goods company?
The median Debt-to-Equity among Consumer Packaged Goods companies is 0.41, based on 1,743 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Valbiotis's current Debt-to-Equity of 0.73 is 78% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Valbiotis and its competitors. For the Consumer Packaged Goods industry, the median Debt-to-Equity is 0.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Valbiotis's current Debt-to-Equity is 0.73, which is 35% above median its own 10-year median of 0.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Valbiotis stock overvalued right now?
Based on GuruFocus' analysis, Valbiotis (XPAR:ALVAL) is currently considered Possible Value Trap. The stock's GF Value™ is €1.46, compared to a current price of €0.76 — trading 47.9% below its estimated fair value. The current Debt-to-Equity is 0.73, which is 35% above median its 10-year median of 0.54 and 78% above the Consumer Packaged Goods industry median of 0.41. Valbiotis' overall GF Score™ is 48/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Valbiotis (XPAR:ALVAL), the current Debt-to-Equity is 0.73 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Valbiotis (XPAR:ALVAL) Overvalued in 2026?
Based on GuruFocus' analysis, Valbiotis stock appears to be undervalued.
The current stock price of €0.76 is trading 47.9% below its estimated GF Value™ of €1.46.
GuruFocus considers Valbiotis to be Possible Value Trap.
Key valuation signals for XPAR:ALVAL:
Debt-to-Equity: 0.73 (35% above median its 10-year median of 0.54)
GF Value™: €1.46 vs. price of €0.76 (47.9% below fair value)
Industry Position: 78% above the Consumer Packaged Goods median (#1188 of 1743)
No single metric tells the full story. See the XPAR:ALVAL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Valbiotis SA is a research & development company. It is engaged in scientific innovation for preventing and combating metabolic diseases. Valbiotis has adopted an approach, aiming to revolutionize healthcare by developing a new class of Nutrition Health products designed to reduce the risk of metabolic diseases, based on a multi-target approach by the use of plant-based ingredients.
48GF Score
Get the complete analysis for XPAR:ALVAL
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAR:ALVAL has been successfully added to your 
